DOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Setting

by Erika Mohr, Johnny Daniels, Busisiwe Beko et al.
PLoS ONE 12(5): e0178054, – Published: May 18, 2017

13 pp. 2.1 MB

Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. The authors assessed the impact of self-administered treatment (SAT) in a South African township with high rates of RR-TB and HIV. They conclude that the introduction of SAT during the continuation phase of RR-TB treatment does not adversely affect final RR-TB treatment outcomes in a high TB and HIV-burden setting. This differentiated, patient-centred model of care could be considered in RR-TB programmes to decrease the burden of DOT on patients and health facilities.

(Visited 28 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.